Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.